Salivary Gland Carcinoma Diagnostics and Treatment

Salivary gland carcinomas encompass a diverse group of malignant neoplasms arising in major and minor salivary glands, characterised by wide histological heterogeneity and variable clinical behaviour. Accurate diagnosis relies on a combination of clinical assessment, imaging modalities such as ultrasound, magnetic resonance imaging and positron emission tomography, and cytological evaluation via fine needle aspiration. Histopathological examination and immunohistochemistry further refine subtype classification and guide management. Molecular profiling through next-generation sequencing has unveiled key genetic drivers and fusion events, enabling risk stratification and identification of therapeutic targets. Primary treatment remains surgical excision with an emphasis on nerve preservation in the parotid region, complemented by adjuvant radiotherapy for high-grade or margin-positive tumours. Systemic therapies have historically been limited, but evolving knowledge of actionable mutations and signalling pathways has led to the introduction of targeted agents and immunomodulatory approaches. Multidisciplinary care, tailored surveillance and incorporation of emerging biomarkers are critical for optimising outcomes in these rare malignancies.

Research from Nature Portfolio

Recent studies have elucidated novel oncogenic mechanisms in salivary gland carcinomas. In acinic cell carcinoma, recurrent chromosomal rearrangements have been shown to hijack native enhancer elements and drive overexpression of the transcription factor NR4A3, promoting tumour cell proliferation and offering a potential diagnostic marker. In myoepithelial carcinoma, integrated genomic analyses revealed a predominance of PLAG1 gene fusions—most notably FGFR1-PLAG1 and TGFBR3-PLAG1—that underlie tumourigenesis and serve as hallmarks of this aggressive subtype. These findings provide a molecular framework for precision diagnostics and lay the groundwork for targeted inhibition of fusion-driven oncogenic pathways.

Salivary Gland Carcinoma Diagnostics and Treatment publication trend

The graph below shows the total number of articles in salivary gland carcinoma diagnostics and treatment across all publications each year (not limited to Nature Index journals).

Technical terms

Fine needle aspiration cytology (FNA): A minimally invasive technique to obtain cellular material from salivary lesions for cytological evaluation.

Next-generation sequencing (NGS): High-throughput DNA sequencing methods used to identify mutations, gene fusions and copy number alterations in tumour samples.

Epithelial-mesenchymal transition (EMT): A biological process by which epithelial cells acquire mesenchymal traits, contributing to tumour invasion and metastasis.

Enhancer hijacking: A genetic event in which regulatory DNA elements are relocated to activate oncogene expression in cancer cells.

cGAS-STING pathway: An innate immune signalling cascade triggered by cytosolic DNA that can induce antitumour immune responses.

References

1. Increased retinoic acid signaling decreases lung metastasis in salivary adenoid cystic carcinoma by inhibiting the noncanonical Notch1 pathway. Experimental & Molecular Medicine (2023).
2. Inhibition of CDH11 Activates cGAS‐STING by Stimulating Branched Chain Amino Acid Catabolism and Mitigates Lung Metastasis of Adenoid Cystic Carcinoma. Advanced Science (2024).
3. Genetic hallmarks of recurrent/metastatic adenoid cystic carcinoma. Journal of Clinical Investigation (2019).
4. Enhancer hijacking activates oncogenic transcription factor NR4A3 in acinic cell carcinomas of the salivary glands. Nature Communications (2019).
5. Multi-dimensional genomic analysis of myoepithelial carcinoma identifies prevalent oncogenic gene fusions. Nature Communications (2017).